Intelligent Bio Solutions raised approximately $5.0 million in gross proceeds through a private Placement involving 2,036,659 Pre-Funded Warrants and accompanying Series N-1 and Series N-2 warrants. The proceeds are intended for Working Capital and general corporate purposes, while additional Warrant terms depend on regulatory clearance, Shareholder approval and resale registration.

Key Highlights

  • Each private-placement unit carried a combined purchase price of $2.455.
  • Series N-1 and Series N-2 warrants each cover 2,036,659 common-stock shares.
  • The company agreed to file a resale registration statement by September 15, 2026, and seek effectiveness by October 15, 2026.

Intelligent Bio Solutions Inc. (NASDAQ: INBS) generated approximately $5.0 million in gross proceeds from a private placement that closed September 2, 2026. The transaction involved one institutional investor and included Pre-Funded Warrants instead of common stock at closing. Intelligent Bio Solutions intends to use the net proceeds for working capital and general corporate purposes.

Private Placement Structure

Each warrant series allows the purchase of up to an aggregate of 2,036,659 common-stock shares. The combined price for one common share or one Pre-Funded Warrant, together with one Series N-1 Warrant and one Series N-2 Warrant, was $2.455. At the closing, Intelligent Bio Solutions issued 2,036,659 Pre-Funded Warrants instead of common stock. Each Pre-Funded Warrant can be exchanged for one common-stock share at $0.01 per share, subject to adjustments under its terms. The warrants remain exercisable until they have been exercised in full. Both warrant series have five-year terms beginning after the registration statement covering their underlying shares is declared effective.

Conditions On Warrant Exercise

Series N-2 Warrant exercise begins on and after shareholder approval for issuing the shares underlying those warrants. The different exercise conditions attach separate milestones to the two warrant series. The company agreed to submit a resale registration statement covering the common stock sold to investors and shares issuable upon warrant exercise by September 15, 2026.

Placement Agent Compensation

Ladenburg Thalmann & Co. Inc. served under a placement agency agreement dated August 31, 2026. The agreement provides for an 8.0% cash fee based on gross offering proceeds and a 1.0% management fee based on those proceeds. The Placement Agent Warrants carry an exercise price of $3.06875 per share and a five-year term beginning after the registration statement covering their underlying shares is declared effective. Intelligent Bio Solutions also agreed to reimburse placement-agent expenses up to $145,000.